Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Vaccines news

Show

From To
Another HIV vaccine efficacy trial will start this year

A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study

Published
26 July 2017
By
Gus Cairns
The 2017 Pipeline Report

Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

Published
19 July 2017
From
Treatment Action Group
Immune system may keep body from neutralizing HIV-1 virus

Researchers at the University of Colorado Anschutz Medical Campus have discovered that a process protecting the body from autoimmune disease appears to prevent it from creating antibodies that can neutralize the HIV-1 virus, a finding that could possibly help lead to a vaccine that stimulates production of these antibodies.

Published
11 July 2017
From
Eurekalert Medicine & Health
First vaccine shows gonorrhoea protection

A vaccine has for the first time been shown to protect against gonorrhoea, scientists in New Zealand say. The vaccine, originally developed to stop an outbreak of meningitis B, was given to about a million adolescents in New Zealand between 2004 and 2006. Researchers at the University of Auckland analysed data from sexual health clinics and found gonorrhoea cases had fallen 31% in those vaccinated. The meachanism of protection is unknown. This particular vaccine is no longer available but the UK has been using a similar vaccine, though whether it will protect is also unknown.

Published
11 July 2017
From
BBC
Does it ever make sense to target HPV screening at HIV-infected individuals?

A number of recent studies have considered the case for HPV-related cancer prevention interventions that are targeted at specific populations. A recent study suggests that, given their more rapid progression to precancerous conditions, HIV positive women in sub-Saharan Africa should be given the multivalent HP)V vaccine, as it already is to HIV-positive MSM in some high-income settings.

Published
05 July 2017
From
BMJ
HIV vaccine boost generates higher immune response 6 to 8 years later

Boosting Thai participants from the RV144 HIV vaccine trial 6 to 8 years after their initial vaccination generated higher immune responses compared with those seen immediately after RV144; however, these humoral and CD4+ T cell responses were short-lived and did not grow after subsequent boosting, according to recent data published in The Journal of Infectious Diseases.

Published
03 July 2017
From
Healio
Should everyone be getting the HIV prevention pill as part of this HIV vaccine study?

More than 500 people have signed up since December to be part of the country’s largest HIV vaccine trial, but some experts are crying foul over what they say is unequal access to the HIV prevention pill among participants.

Published
30 June 2017
From
Bhekisisa
Top HIV expert is not donating to crowdfunding HIV vaccine campaign, says it's "Fake News"

Dr. Carl W. Dieffenbach, head of the AIDS division of the US National Institutes of Health, has denounced an HIV vaccine crowdfunding campaign involving prominent stars. The major fundraising #ENDHIV campaign which features SIA, the campaign’s ambassador. Other celebrities include Zoe Saldana and Julianne Moore. Dr Dieffenbach's assessment is not pointed at the celebrities nor the organisation behind the campaign. It’s about the research of scientist, Dr. Paul, whom Dieffenbach asserts “is wrong” in his direction towards discovering the vaccine or cure promoted by the video and the campaign’s website www.endhiv.com. Yet, the #ENDHIV video calls Dr. Paul’s work “a promising new AIDS cure.”

Published
17 June 2017
From
imstilljosh
Slow start to landmark South African HIV vaccine trial

Stringent global standards to enlist participants are slowing the process of volunteering to participate in South Africa’s ground-breaking HIV vaccine trial, known as HVTN 702.

Published
02 June 2017
From
Medical Brief
HIV 'fingerprint' tool could greatly assist vaccine development

A method that quickly fingerprints the shield of sugar molecules that helps HIV evade immune system antibodies could be very useful to vaccine developers.

Published
26 May 2017
From
HIV / AIDS News From Medical News Today
← First12345...36Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.